 Home > Active Ingredient News > Immunology News > Arthritis&Rheumatology: Relationship between pregnancy outcome of women with psoriatic arthritis and anti-rheumatic treatment and timing

Arthritis&Rheumatology: Relationship between pregnancy outcome of women with psoriatic arthritis and anti-rheumatic treatment and timing

 Last Update: 2021-11-12
 Source: Internet
 Author: User

Tags

2 year programs

1 4 addition

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Objective: To evaluate the pregnancy outcome of psoriatic arthritis ( PSA ) before and during pregnancy with anti-rheumatic treatment (as an approximate estimate of disease severity) compared to non- PsA pregnancy, especially the time and type of anti-rheumatic treatment The relationship between
.

Methods: 2007-2017 Swedish national registries based cohort study, included 921 Li PsA pregnancy and 9210 cases of non- PSA pregnancy (by 1:10 year and parity on maternal age and match)
.

The researchers estimated the overall adjusted odds ratio (aOR) and stratified according to whether anti-rheumatic treatment, time and type

Methods: 2007-2017 Swedish national registries based cohort study, included 921 Li PsA pregnancy and 9210 cases of non- PSA pregnancy (by 1:10 year and parity on maternal age and match)

Results: Compared with non- PsA pregnancies, women with PsA weighed more, smoked more often, and had a higher rate of being diagnosed with pre-pregnancy hypertension and diabetes

Conclusion: Compared with non- PsA pregnancy, the risk of preterm birth and cesarean section is mostly increased in people who receive anti-rheumatic treatments (especially biologics) during pregnancy

Source:

Remaeus K, Johansson K, Granath F, Stephansson O, Hellgren K.

Pregnancy outcomes in women with psoriatic arthritis with respect to presence and timing of antirheumatic treatment.
Arthritis Rheumatol.

Remaeus K, Johansson K, Granath F, Stephansson O, Hellgren K.
Pregnancy outcomes in women with psoriatic arthritis with respect to presence and timing of antirheumatic treatment.
Arthritis Rheumatol.
2021 Oct 20.
doi: 10.
1002/art.
41985.
Epub ahead of print.
PMID: 34668647.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.